Skip to main content
Inmune Bio, Inc. logo

Inmune Bio, Inc. — Investor Relations & Filings

Ticker · INMB ISIN · US45782T1051 US Manufacturing
Filings indexed 571 across all filing types
Latest filing 2026-04-23 Proxy Solicitation & In…
Country US United States of America
Listing US INMB

About Inmune Bio, Inc.

https://www.inmunebio.com/

Inmune Bio, Inc. is a clinical-stage biotechnology company that develops therapies by reprogramming the patient's innate immune system to fight disease. The company's pipeline is focused on treating cancer and neurodegenerative disorders, particularly Alzheimer's disease. Its lead product candidates include XPro1595, a selective inhibitor of soluble Tumor Necrosis Factor (TNF) for treating neuroinflammation, and INKmune®, a tumor-agnostic therapy designed to prime a patient's natural killer (NK) cells to attack cancer. Inmune Bio's clinical development approach prioritizes matching a drug's mechanism of action to patient biology and using patient-centric outcome metrics.

Recent filings

Filing Released Lang Actions
DEF 14A - Inmune Bio, Inc. (0001711754) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
8-K - INMUNE BIO, INC. (0001711754) (Filer)
Regulatory Filings
2026-02-27 English
8-K - INMUNE BIO, INC. (0001711754) (Filer)
Regulatory Filings
2026-02-23 English
8-K - INMUNE BIO, INC. (0001711754) (Filer)
Regulatory Filings
2026-02-19 English
8-K Filing
Regulatory Filings
2026-02-13 English
8-K Filing
Regulatory Filings
2026-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.